Animal Whole Blood Anticoagulant Activity Testing: Principles, Methods, and Applications

Animal whole blood anticoagulant activity testing is an in vitro biological evaluation used to quantify how anticoagulant substances, surface-modified biomaterials, and blood-contacting medical devices interfere with the coagulation cascade in fresh animal blood. Performed in accordance with ISO 10993-4, ISO 10993-12, and related hemocompatibility standards, the assay measures coagulation parameters such as PT, APTT, TT, and fibrinogen to support material screening, product development, and regulatory submissions. This article explains the testing principle, sample types, testing items, methodology, and typical applications of the assay.

Technical Overview

Animal whole blood anticoagulant activity testing is an in vitro biological evaluation that assesses the capacity of a test article to delay, inhibit, or modify clot formation when placed in direct contact with fresh whole blood collected from healthy animals such as rabbits, rats, sheep, goats, or pigs. The test falls within the coagulation category of hemocompatibility evaluation described in ISO 10993-4 and is routinely performed by accredited third-party laboratories or manufacturers' biological safety laboratories under approved animal ethics protocols.

The coagulation cascade consists of the intrinsic pathway (contact activation factors XII, XI, IX, and VIII), the extrinsic pathway (tissue factor and factor VII), and the common pathway (factors X and V, prothrombin, and fibrinogen), all converging on the thrombin-mediated conversion of fibrinogen into fibrin. By measuring the time required for clot formation after pathway-specific activation, or by monitoring whole blood clotting directly, the assay reveals whether a material or compound accelerates, inhibits, or leaves unaffected each arm of the cascade.

• Prolonged APTT with normal PT suggests inhibition of the intrinsic pathway, a pattern characteristic of heparin-like activity.
• Prolonged PT indicates interference with the extrinsic pathway or the common pathway.
• Prolonged TT reflects direct inhibition of thrombin activity or impaired fibrin polymerization.
• Reduced fibrinogen concentration indicates clotting factor consumption during coagulation or fibrinolytic degradation.

The principal reference standards for this testing include ISO 10993-4 for the selection of blood interaction tests, ISO 10993-12 for sample preparation and reference materials, GB/T 16886.4 as the corresponding national adoption, and ASTM F756 as a complementary practice for assessing hemolytic properties of materials. Pharmacopoeial heparin potency methods based on sheep plasma clotting may also be referenced when evaluating anticoagulant drug substances.

Testing Samples

Anticoagulant Substances and Extracts

Heparin sodium, low-molecular-weight heparin, citrate and EDTA salts, sulfated polysaccharides, plant- or marine-derived natural anticoagulants, and small-molecule or peptide anticoagulant candidates under development. Soluble test articles are typically dosed directly into citrated whole blood to establish concentration-response relationships.

Blood-Contacting Medical Devices

Intravascular catheters, guidewires, stents and stent grafts, vascular grafts, hemodialyzers, oxygenators, extracorporeal circulation tubing sets, blood bags, infusion sets, and blood filtration devices. Devices may be evaluated as intact products, cut segments, or extracts prepared under clinically justified conditions.

Surface Coatings and Modified Biomaterials

Heparinized, phosphorylcholine, hydrophilic-lubricious, or other antithrombotic coatings applied to polymers, metals, and hydrogels. The test verifies that functional anticoagulant activity is retained after manufacturing, sterilization, packaging, and storage.

Wound Care and Hemostatic Products

Hemostatic dressings and topical products can be screened to confirm the absence of anticoagulant leachables that would compromise their intended hemostatic performance.

Testing Items

Depending on the study objective, the evaluation may include one or more of the following parameters:

• Prothrombin time (PT), reflecting the extrinsic and common pathways.
• Activated partial thromboplastin time (APTT), reflecting the intrinsic and common pathways.
• Thrombin time (TT), reflecting thrombin activity and fibrin formation.
• Fibrinogen concentration (FIB), typically determined by the Clauss method.
• Whole blood clotting time and activated clotting time (ACT).
• Plasma recalcification time for citrated samples.
• Thrombus mass and circuit occlusion time in dynamic flow models.
• Platelet count and platelet adhesion as complementary indicators.
• Hemolysis ratio as a complementary hemocompatibility measurement.

Testing Methods

Sample Preparation and Extraction

Test articles are prepared according to ISO 10993-12, using a standard surface-area-to-volume ratio, for example 3 cm² per mL for flat materials or 0.1 to 0.2 g per mL for irregular samples, or the internal cavity volume for hollow devices. Contact media include citrated whole blood, citrated platelet-poor plasma, or physiological saline, with incubation conditions, commonly 37°C for 30 minutes to 24 hours, justified by the intended clinical use. Samples should be tested in their final, sterilized condition so the evaluation reflects the product as supplied.

Blood Collection and Handling

Fresh blood is collected from healthy animals via clean venipuncture using large-bore needles to minimize contact activation and hemolysis. Blood is anticoagulated with 3.2% (0.109 mol/L) trisodium citrate at a 1:9 citrate-to-blood ratio, gently mixed, and held at room temperature, with testing initiated within a validated window, typically one to two hours after collection. EDTA and heparin collection tubes are avoided because both agents directly interfere with downstream coagulation measurements. Baseline coagulation values of each blood lot are verified before use.

Static Contact Incubation

In the static design, the test material, its extract, or a dosed solution is incubated with citrated whole blood at 37°C for defined contact periods, such as 15, 30, 60, and 120 minutes. The blood is then centrifuged to obtain platelet-poor plasma, and PT, APTT, TT, and FIB are measured on an automated coagulation analyzer using mechanical or optical clot detection. For whole blood clotting time, non-anticoagulated blood is applied directly onto the material surface and timed by the tilt method until clot formation is observed. Each run includes a blood-only blank, a negative control material such as high-density polyethylene, and a positive anticoagulant control such as a heparin reference standard.

Dynamic Flow Models

For devices intended to contact flowing blood, a Chandler loop, parallel-plate flow chamber, or custom flow circuit operating at physiologically relevant shear rates is employed. Anticoagulated or minimally anticoagulated animal blood is recirculated through the device or across the test surface, after which thrombus mass, pressure drop or occlusion time, clotting times, platelet count, and free hemoglobin are determined. Dynamic testing better captures convective transport, shear-induced platelet activation, and washout effects encountered in clinical use.

Data Analysis and Reporting

Anticoagulant activity is expressed as the prolongation ratio of clotting times relative to the negative control, as a percentage of activity against a heparin reference standard, or as a concentration-response relationship such as an IC50 value for soluble compounds. Results are evaluated statistically using appropriate tests, for example a t-test or analysis of variance, with significance conventionally accepted at a probability level below 0.05. The final report documents the animal source and blood handling conditions, contact parameters, reagents and instruments, control performance, individual and mean values, and a conclusion on anticoagulant activity relative to controls.

Applications

The test supports a broad range of development and regulatory activities across the pharmaceutical, biomaterials, and medical device sectors:

• Screening and comparative potency assessment of anticoagulant drug substances and natural anticoagulant extracts.
• Functional verification of heparin and other antithrombotic surface coatings on catheters, stents, and extracorporeal circuits.
• Generation of hemocompatibility data for biological evaluation files supporting device registration submissions.
• Comparison of biomaterial surface chemistries, sterilization methods, and storage conditions during research and development.
• Confirmation that hemostatic and wound care products do not release unintended anticoagulant leachables.
• Academic and preclinical pharmacology studies investigating the mechanism of novel antithrombotic agents.

FAQ

Which animal species are most commonly used?

Rabbit and rat whole blood are widely used for material contact studies because of ethical acceptability and manageable blood volume requirements. Sheep and goat blood suit heparin potency assays and larger-volume testing, while porcine blood is increasingly preferred for cardiovascular devices because its hematologic characteristics closely resemble those of human blood. Species selection is documented and scientifically justified in the test plan.

Why is sodium citrate used instead of EDTA or heparin for blood collection?

Citrate reversibly chelates calcium, allowing coagulation to be re-initiated in the assay by the addition of calcium or thrombin, and it does not directly inhibit the enzymatic reactions measured by PT, APTT, and TT. EDTA binds calcium irreversibly and heparin inhibits thrombin, so either agent would confound the measurement of the test article's own effect on coagulation.

How is anticoagulant activity distinguished from procoagulant activity?

Anticoagulant activity is indicated by significantly prolonged PT, APTT, or TT, increased whole blood clotting time, reduced thrombus mass, and preserved fibrinogen relative to controls. Procoagulant or thrombogenic behavior is indicated by shortened clotting times, increased thrombus mass, and fibrinogen consumption. When no statistically significant difference from the negative control is observed, the material is classified as inactive or inert with respect to coagulation.

What sample quantities and conditions should be submitted for testing?

Testing generally requires enough material to provide replicate samples, typically at least three per condition, each incubated in triplicate blood replicates. Devices should be supplied in their final, sterilized, packaged state, together with any reference standard or comparator product required for potency comparison. The laboratory confirms dimensions, extraction ratios, and contact conditions in the study protocol before initiation.

How does this in vitro test relate to in vivo thrombogenicity testing?

The in vitro whole blood assay is faster, more controllable, and more animal-sparing, making it well suited to early screening and coating verification. However, it excludes vascular endothelium, physiological flow regulation, and biological repair mechanisms. ISO 10993-4 therefore positions in vitro coagulation testing as one component of an overall hemocompatibility strategy, which may be complemented by in vivo thrombogenicity studies for high-risk, long-duration blood-contacting devices.